top of page

Nanotherapeutics lab

Publications

cover.tif.jpg

2024

Stylianou M, Kisby T*, Despotopoulou D, Parker H, Thawley A, Arashvand K, Lozano N, MacDonald AS, Kostarelos K*.

Engineering the glioblastoma microenvironment using TLR7/8 agonist-complexed graphene oxide nanosheets.

Cell Reports Physical Science Volume 6, Issue 1102342: 2025

2023

Sharp PS, Stylianou M, Arellano LM, Neves JC, Gravagnuolo AM, Dodd A, Barr K, Lozano N, Kisby T*, Kostarelos K*.

Graphene Oxide Nanoscale Platform Enhances the Anti‐Cancer Properties of Bortezomib in Glioblastoma Models.

Advanced Healthcare Materials. 2023 Jan;12(3):2201968.

Despotopoulou D, Stylianou M, Arellano LM, Kisby T, Lozano N, Kostarelos K*.

Engineering of a graphene oxide-based two-dimensional platform for immune activation and modulation.

bioRxiv. 2023 08.22.553542;

2021

Kisby T, Yilmazer A, Kostarelos K*.

Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. Nature Nanotechnology. 2021 Aug;16(8):843-50.

Kisby T, de Lázaro I, Fisch S, Cartwright EJ, Cossu G, Kostarelos K*.

Adenoviral mediated delivery of OSKM factors induces partial reprogramming of mouse cardiac cells in vivo.

Advanced Therapeutics. 2021 Feb;4(2):2000141.

Kisby T, De Lázaro I, Stylianou M, Cossu G, Kostarelos K*.

Transient reprogramming of postnatal cardiomyocytes to a dedifferentiated state.

PloS one. 2021 May 5;16(5):e0251054.

2020

Shin Y, Vranic S, Just-Baringo X, Gali SM, Kisby T, Chen Y, Gkoutzidou A, Prestat E, Beljonne D, Larrosa I*, Kostarelos K*, Casiraghi C*.

Stable, concentrated, biocompatible, and defect-free graphene dispersions with positive charge.

Nanoscale. 2020 12(23):12383-94.

bottom of page